Relationship between eosinophilia and levels of chemokines (CCL5 and CCL11) and IL-5 in bronchoalveolar lavage fluid of patients with mustard gas-induced pulmonary fibrosis

Journal of Clinical Immunology

Volumn 28, Issue 4, 2008, Pages 298-305

  Emad, Ali ^a   Emad, Yasaman ^b  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHIRAZ UNIVERSITY   (Iran)

Author keywords

Eotaxin; IL 5; Mustard; RANTES

Indexed keywords

EOTAXIN; INTERLEUKIN 5; MUSTARD GAS; RANTES;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE RELEASE; EOSINOPHIL COUNT; EOSINOPHILIA; EOSINOPHILIC ALVEOLITIS; HUMAN; HUMAN CELL; LUNG ALVEOLITIS; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG LAVAGE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE;

ADULT; BRONCHOALVEOLAR LAVAGE FLUID; CHEMICAL WARFARE AGENTS; CHEMOKINE CCL11; CHEMOKINE CCL5; CHEMOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; HUMANS; INTERLEUKIN-5; MUSTARD GAS; PULMONARY EOSINOPHILIA; PULMONARY FIBROSIS; RESPIRATORY FUNCTION TESTS;

EID: 46749101779     PISSN: 02719142     EISSN: 15732592     Source Type: Journal    
DOI: 10.1007/s10875-007-9109-8     Document Type: Article

References (34)

1. Aasted A, Darre E, Wulf HC. Mustard gas: clinical, toxicological and mutagenic aspects based on modern experience. Ann Plastic Surg 1987;19:330-3.
2. Calvet JH, Jarreau HP, Levame M, Lorino H, d'Ortho MP, Harf A, et al. Acute and chronic effects of sulfur mustard intoxication in the guinea pig. J Appl Physiol 1994;76:681-8.
3. Papirmeister B, Gross CL, Meier HL, Petrali JP, Johnson JB. Molecular basis for mustard-induced vesication. Fundam Appl Toxicol 1985;5:S134-49.
4. Anderson DR, Byers SL, Vesely KR. Treatment of sulfur mustard (HD)-induced lung injuries. J Appl Toxicol 2000;20:S129.
5. Emad A, Rezaian GR. The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: analysis of 197 cases. Chest 1997;112:734-8.
6. Emad A, Rezaian GR. Characteristics of bronchoalveolar lavage fluid in patients with sulfur mustard gas-induced asthma or chronic bronchitis. Am J Med 1999;106:689-90.
7. Emad A, Rezaian GR. Immunoglobulins and cellular constituents of the BAL fluid of patients with sulfur mustard gas-induced pulmonary fibrosis. Chest 1999;115:1346-51.
8. Czarnobilska E, Obtulowicz K. Eosinophil in allergic and non-allergic inflammation. Przegl Lek 2005;62(12):1484-7.
9. Worthylake RA, Burridge K. Leukocyte transendothelial migration: orchestrating the underlying molecular machinery. Curr Opin Cell Biol 2001;31:569-77.
10. Emad A, Rezaian GR. The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: analysis of 197 cases. Chest 1997;112:734-8.
11. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. Am J Respir Crit Care Med 2000;161:646-64.
12. Miller MR, Crapo R, Hankinson J, Brusasco V, Burgos F, Casaburi R, et al. General considerations for lung function testing. Eur Respir J 2005;26:153-61.
13. Cotes JE, Chinn DJ, Quanjer PhH, Roca J, Yernault J-C. Standardization of the measurement of transfer factor (diffusing capacity). Report working party, standardization of lung function tests, European Community for steel and coal. Official Statement of the European respiratory Society. Eur Respir J 1993;16:41-52.
14. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J 2005;26:948-68.
15. Agostini C, Meneghin A, Semenzato G. T-lymphocytes and cytokines in sarcoidosis. Curr Opin Pulm Med 2002;8:435-40 (Sep. Review).
16. Emad A, Emad Y. Increased in CD8 T lymphocytes in the BAL fluid of patients with sulfur mustard gas-induced pulmonary fibrosis. Res Med 2007;101:786-92.
17. Emad A, Emad Y. Levels of cytokines in bronchoalveolar lavage (BAL) fluid in patients with pulmonary fibrosis due to sulfur mustard gas inhalation. J Interferon Cytokine Res 2007;27:38-43.
18. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517.
19. Moser B, Willimann K. Chemokines: role in inflammation and immune surveillance. Ann Rheum Dis 2004;63:84-9.
20. The BAL Cooperative Group Steering Committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am Rev Respir Dis 1990;141:S169-202.
21. Manzo A, Caporali R, Montecucco C, Pitzalis C. Role of chemokines and chemokine receptors in regulating specific leukocyte trafficking in the immune/inflammatory response. Clin Exp Rheumatol 2003;21:501-8.
22. Olson TS, Ley K. Chemokines and chemokine receptors in leukocyte trafficking. Am J Physiol Regul Integr Comp Physiol 2002;283:R7-28.
23. Ahn YT, Huang B, McPherson L, Clayberger C, Krensky AM. Dynamic interplay of transcriptional machinery and chromatin regulates "late" expression of the chemokine RANTES in T lymphocytes. Mol Cell Biol 2007;27:253-66.
24. Chiba T, Kamada Y, Saito N, Oyamada H, Ueki S, Kobayashi Y, et al. RANTES and eotaxin enhance CD11b and CD18 expression on eosinophils from allergic patients with eosinophilia in the application of whole Blood flow cytometry analysis. Int Arch Allergy Immunol 2005;137(Suppl 1):12-6.
25. Ebisawa M, Yamada T, Bickel C, Klunk D, Schleimer RP. Eosinophil transendothelial migration induced by cytokines. III. Effect of the chemokine RANTES. J Immunol 1994;153:2153-60.
26. Alam R, Stafford S, Forsythe P, Grant GA. RANTES is a chemotactic and activating factor for eosinophils. J Immunol 1993;150:3442-7.
27. Costa GG, Silva RM, Franco-Penteado CF, Antunes E, Ferreira HH. Interactions between eotaxin and interleukin-5 in the chemotaxis of primed and non-primed human eosinophils. Eur J Pharmacol 2007;566:200-5.
28. Itakura A, Kikuchi Y, Kouro T, Ikutani M, Takaki S, Askenase PW, et al. Interleukin 5 plays an essential role in elicitation of contact sensitivity through dual effects on eosinophils and B-1 cells. Int Arch Allergy Immunol 2006;140(Suppl 1):8-16.
29. Umetsu DT. Revising the immunological theories of asthma and allergy. Lancet 2005;365(9454):98-100.
30. Kaatz M, Berod L, Czech W, Idzko M, Lagadari M, Bauer A, et al. Interleukin-5, interleukin-3 and granulocyte-macrophage colony-stimulating factor prime actin polymerization in human eosinophils: a study with hypodense and normodense eosinophils from patients with atopic dermatitis. Int J Mol Med 2004;14(6):1055-60.
31. Fulkerson PC, Fischetti CA, McBride ML, Hassman LM, Hogan SP, Rothenberg ME. A central regulatory role for eosinophils and the eotaxin/CCR3 axis in chronic experimental allergic airway inflammation. Proc Natl Acad Sci USA 2006;103(44):16418-23.
32. Lampinen M, Rak S, Venge P. The role of interleukin-5, interleukin-8 and RANTES in the chemotactic attraction of eosinophils to the allergic lung. Clin Exp Allergy 1999;29:314-22.
33. Moore BB, Coffey MJ, Christensen P, Sitterding S, Ngan R, Wilke CA, et al. GM-CSF regulates bleomycin-induced pulmonary fibrosis via a prostaglandin-dependent mechanism. J Immunol 2000;165:4032-9.
34. Hao H, Cohen DA, Jennings CD, Bryson JS, Kaplan AM. Bleomycin-induced pulmonary fibrosis. is independent of eosinophils. J Leukoc Biol 2000;68:515-21.